Intravenous Iron Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Iron Dextran, Ferric Gluconate, Iron Sucrose, Ferric Carboxymaltos, Iron Isomaltoside 1000, Ferumoxytol), By Application (Intestinal Malabsorption Syndromes, Inflammatory Diseases, Gastrectomy/Bariatric Surgery, Anemia, Osier-Weber-Rendu Disease, Angiodysplasia, Pregnancy, Others), By Region and Competition, 2020-2030F

Market Overview

Global Intravenous Iron Drugs Market was valued at USD 2.46 Billion in 2024 and is expected to reach USD 3.39 Billion by 2030 with a CAGR of 5.70%. Intravenous iron therapy has become an essential treatment option for patients who are unable to tolerate or do not respond adequately to oral iron supplements. This trend is particularly evident in hospital settings, dialysis centers, and oncology departments, where rapid iron repletion is often critical.

A major driver of the market is the rising incidence of anemia associated with chronic diseases such as CKD, inflammatory bowel disease (IBD), cancer, and heart failure. The growing global burden of these conditions has increased the demand for faster and more effective iron supplementation therapies. In addition, improvements in the safety profiles of newer IV iron drugs have enhanced their clinical adoption. Compared to older formulations, newer products are associated with fewer adverse reactions, reducing the need for test dosing and improving patient compliance.

Key Market Drivers

Growth in Healthcare Industry

The rapid expansion of the global healthcare industry has emerged as a key driver of the intravenous (IV) iron drugs market. The global healthcare industry generates annual sales exceeding USD 4 trillion. Among its most significant and lucrative segments are pharmaceuticals and biotechnology, which account for nearly USD 850 billion, and medical technology and diagnostics, contributing over USD 400 billion. This growth is primarily fueled by increasing investments in healthcare infrastructure, rising patient awareness, and the expanding burden of chronic diseases such as chronic kidney disease (CKD), inflammatory bowel disease (IBD), and cancer all of which are frequently associated with iron-deficiency anemia. As healthcare systems strengthen and access to medical services broadens, there is a corresponding rise in the diagnosis and treatment of iron deficiency, contributing significantly to the demand for IV iron therapies.

Moreover, the proliferation of hospitals, specialty clinics, and diagnostic centers, particularly in emerging economies, has enhanced the administration of parenteral therapies, including intravenous iron formulations. By 2026, the total number of hospitals worldwide is expected to reach 215,977. Although most regions are projected to witness a decline in hospital numbers between 2021 and 2026, the overall global increase is driven exclusively by growth in two key regions: the Far East & China and Africa & the Middle East. IV iron drugs are often preferred over oral iron supplements in clinical settings due to their rapid replenishment capabilities and effectiveness in patients who cannot tolerate or absorb oral iron. The increasing availability of advanced infusion facilities and trained healthcare professionals further supports the widespread use of these drugs.

Surge in Technological Advancements

The global intravenous (IV) iron drugs market is experiencing robust growth, largely propelled by a surge in technological advancements. Innovations in formulation technology, drug delivery systems, and diagnostic tools are significantly enhancing the safety, efficacy, and patient compliance of IV iron therapies, thereby driving market expansion. In 2020, Garbowski and colleagues demonstrated that ferric derisomaltose (FDI) resulted in significantly lower levels of non-transferrin-bound iron (NTBI), an indicator of labile iron showing a 7-fold reduction compared to ferric carboxymaltose (FCM) and a 9-fold reduction compared to iron sucrose. Moreover, FDI exhibited a substantially longer half-life (20.3 hours), relative to FCM (6.82 hours) and iron sucrose (3.43 hours). These findings suggest that, among the three contemporary intravenous iron formulations, FDI offers the highest in vivo molecular stability.

One of the key developments has been the introduction of next-generation IV iron formulations, such as ferric carboxymaltose and ferumoxytol. These advanced compounds offer improved pharmacokinetic profiles, allowing for higher doses to be administered in a single infusion with reduced risk of adverse reactions. Such innovations are particularly beneficial in managing iron deficiency anemia in chronic kidney disease, cancer, and gastrointestinal disorders, where rapid repletion of iron stores is critical.

Download Free Sample Report

Key Market Challenges

High Cost of Treatment

One of the primary challenges impeding the growth of the global intravenous iron drugs market is the high cost associated with treatment. Intravenous iron therapy, particularly with newer formulations such as ferric carboxymaltose and iron isomaltoside, entails significantly higher costs compared to traditional oral iron supplements. These expenses include not only the drug price but also administration costs, which often require infusion facilities, trained medical personnel, and post-treatment monitoring for adverse reactions.

For healthcare systems, especially in developing countries with limited resources, the financial burden of intravenous iron therapy can strain budgets. Public health programs often prioritize low-cost interventions, which can delay the adoption of intravenous options despite their clinical advantages. Even in developed economies, insurance coverage disparities and high out-of-pocket expenses can limit patient access, particularly in outpatient settings where reimbursement policies may be less comprehensive.

Key Market Trends

Increasing Focus on Maternal and Pediatric Health

The growing global emphasis on maternal and pediatric health has emerged as a significant trend influencing the expansion of the intravenous (IV) iron drugs market. Sub-Saharan Africa experiences the highest maternal and child mortality rates worldwide, accounting for approximately 70% of global maternal deaths. Strategic investments in maternal and child health not only save lives but also deliver significant economic returns, with estimates indicating that each dollar invested can generate up to USD 20 in economic value. Iron deficiency anemia remains a critical public health issue among pregnant women and young children, particularly in low- and middle-income countries. As healthcare systems and policy frameworks increasingly prioritize maternal and child health, the demand for effective iron supplementation therapies, including IV iron formulations, is witnessing notable growth.

In the maternal health segment, intravenous iron is gaining traction as a preferred treatment option for moderate to severe anemia during pregnancy, especially when oral iron supplements prove ineffective or are poorly tolerated. Timely intervention with IV iron not only improves maternal outcomes by reducing the risk of complications such as preterm delivery and postpartum hemorrhage but also supports optimal fetal development. This clinical relevance, coupled with rising awareness among healthcare professionals, is driving broader adoption of IV iron therapies in prenatal care protocols.

Segmental Insights

Product Insights

Based on Product, Iron Dextran have emerged as the fastest growing segment in the Global Intravenous Iron Drugs Market in 2024. This is due to its wide therapeutic applicability, cost-effectiveness, and improved safety profiles in recent formulations. These factors collectively contribute to its rising preference among healthcare providers, particularly in resource-constrained settings and emerging markets. One of the primary drivers behind the growth of iron dextran is its versatility in treating various forms of iron deficiency anemia, especially in patients with chronic conditions such as chronic kidney disease (CKD), inflammatory bowel disease (IBD), and oncology-related anemia. It offers the flexibility of both low- and high-molecular-weight formulations, allowing for tailored dosing strategies that accommodate different clinical scenarios.

Application Insights

Based on Application, Intestinal Malabsorption Syndromes have emerged as the fastest growing segment in the Global Intravenous Iron Drugs Market during the forecast period. This is due to the rising prevalence of gastrointestinal conditions that impair nutrient absorption, particularly iron. Patients suffering from disorders such as celiac disease, inflammatory bowel disease (IBD), Crohn’s disease, and short bowel syndrome often experience chronic iron deficiency anemia that cannot be effectively treated with oral supplements, owing to poor absorption and gastrointestinal intolerance. This has led to a growing clinical reliance on intravenous iron therapies as a more efficient and rapid solution for restoring iron levels in such patients.

Download Free Sample Report

Regional Insights

Based on Region, North America have emerged as the dominating region in the Global Intravenous Iron Drugs Market in 2024. This is due to a combination of advanced healthcare infrastructure, high disease prevalence, and strong reimbursement frameworks. The region benefits from widespread adoption of IV iron therapies in the management of iron deficiency anemia, particularly among patients with chronic kidney disease, cancer, heart failure, and gastrointestinal disorders. The United States, in particular, exhibits a high awareness among healthcare professionals regarding the clinical advantages of intravenous over oral iron formulations, leading to greater prescribing rates.

Recent Development

• In March 2025, Hyloris Pharmaceuticals SA, a specialty biopharmaceutical company focused on meeting unmet medical needs through the enhancement and repurposing of existing drugs, announced its entry into a late-stage research and development collaboration with AFT Pharmaceuticals (AFT). The partnership aims to bring an innovative injectable therapy for iron deficiency (HY-094) to the global market. As part of the agreement, both companies have secured an exclusive global intellectual property license for human use. Under the terms of the collaboration, Hyloris and AFT will jointly develop the product for regulatory approval and worldwide commercialization.
• In March 2024, Cadila Pharmaceuticals, a leading player in the pharmaceutical sector introduced Redshot FCM, an advanced intravenous iron injection formulated with Ferric Carboxymaltose. This next-generation therapy is designed to effectively treat Iron Deficiency Anaemia in both adult and paediatric patients over one year of age, particularly those who are intolerant to oral iron supplements. Redshot FCM offers enhanced safety with low to negligible risk of anaphylaxis and demonstrates superior tolerability. Its intravenous formulation enables the administration of high iron doses in a single sitting, promoting rapid haemoglobin restoration and efficient replenishment of iron reserves.
• In April 2024, Indian medical researchers introduced an affordable single-dose intravenous (IV) iron injection with no reported side effects. Developed by scientists at AIIMS Delhi, this innovation is intended for use among pregnant women. At present, the national healthcare program provides daily iron and folic acid tablets to expectant mothers starting from the second trimester. India continues to bear the highest burden of anaemia among children and pregnant women globally. The IV iron infusion, which delivers a combination of iron and saline directly into the bloodstream, is particularly beneficial for individuals with iron deficiency and chronic kidney disease.
• In June 2024, Menarini Asia-Pacific announced the expansion of its strategic partnership with Pharmacosmos A/S to include exclusive commercialization rights for MonoFer (ferric derisomaltose) in Singapore and Malaysia. This development extends the companies’ successful collaboration for MonoFer in the Australian market. Under the agreement, Menarini will oversee the full spectrum of marketing, sales, and distribution activities for MonoFer in the newly added territories. MonoFer is a next-generation high-dose intravenous (IV) iron therapy that has demonstrated efficacy in treating iron deficiency across a broad range of therapeutic areas. It enables the administration of large iron doses within a short time frame, enhancing treatment efficiency for patients. Currently, MonoFer is approved in over 40 countries worldwide, with more than 46 million doses administered to date.

Key Market Players

• AMAG pharmaceuticals, Inc.
• Vifor Pharma Management Ltd.
• Daiichi Sankyo Company, Limited
• Rockwell Medical Inc.
• Allergan PLC
• Pfizer Inc.
• Nippon Shinyaku Co.
• Novartis International AG
• Takeda Pharmaceutical Company Limited
• Bausch Health Companies Inc.

Report Scope

In this report, the Global Intravenous Iron Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Intravenous Iron Drugs Market, By Product:

o   Iron Dextran

o   Ferric Gluconate

o   Iron Sucrose

o   Ferric Carboxymaltos

o   Iron Isomaltoside 1000

o   Ferumoxytol

• Intravenous Iron Drugs Market, By Application:

o   Intestinal Malabsorption Syndromes

o   Inflammatory Diseases

o   Gastrectomy/Bariatric Surgery

o   Anemia

o   Osier-Weber-Rendu Disease

o   Angiodysplasia

o   Pregnancy

o   Others

• Intravenous Iron Drugs Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Intravenous Iron Drugs Market.

Available Customizations:

Global Intravenous Iron Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Intravenous Iron Drugs Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]